Literature DB >> 32213112

Early hours in the development of high-altitude pulmonary edema: time course and mechanisms.

Erik R Swenson1.   

Abstract

Clinically evident high-altitude pulmonary edema (HAPE) is characterized by severe cyanosis, dyspnea, cough, and difficulty with physical exertion. This usually occurs within 1-2 days of ascent often with the additional stresses of any exercise and hypoventilation of sleep. The earliest events in evolving HAPE progress through clinically silent and then minimally recognized problems. The most important of these events involves an exaggerated elevation of pulmonary artery (PA) pressure in response to the ambient hypoxia. Hypoxic pulmonary vasoconstriction (HPV) is a rapid response with several phases. The first phase in both resistance arterioles and venules occurs within 5-10 min. This is followed by a second phase that further raises PA pressure by another 100% over the next 2-8 h. Combined with vasoconstriction and likely an unevenness in the regional strength of HPV, pressures in some microvascular regions with lesser arterial constriction rise to a level that initiates greater filtration of fluid into the interstitium. As pressures continue to rise local lymphatic clearance rates are exceeded and interstitial fluid begins to accumulate. Beyond elevation of transmural pressure gradients there is a dynamic noninjurious relaxation of microvascular and epithelial cell-cell contacts and an increase in transcellular vesicular transport which accelerate leakage. At some point with further pressure elevation, damage occurs with breaks of the barrier and bleeding into the alveolar space, a late-stage situation termed capillary stress failure. Earlier before there is fluid accumulation, alveolar hypoxia and hyperventilation-induced hypocapnia reduce the capacity of the alveolar epithelium to reabsorb sodium and water back into the interstitial space. More modest ascent which slows the rate of rise in PA pressure and allows for adaptive remodeling of the microvasculature, drugs which lower PA pressure, and those that can enhance fluid reabsorption will all forestall the deleterious early rise of microvascular pressures and diminished active alveolar fluid reabsorption that precede and underlie the development of HAPE.

Entities:  

Keywords:  hemodynamics; high-altitude pulmonary edema; hypoxic pulmonary vasoconstriction; inflammation; lymphatics

Mesh:

Year:  2020        PMID: 32213112     DOI: 10.1152/japplphysiol.00824.2019

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  3 in total

Review 1.  Research Progress on the Mechanism of Right Heart-Related Pulmonary Edema.

Authors:  Yiran Li; Xiaoqiang Wang; Ruiqing Zong; Feixiang Wu; Hai Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-03       Impact factor: 2.650

Review 2.  High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention.

Authors:  Martin Burtscher; Urs Hefti; Jacqueline Pichler Hefti
Journal:  Sports Med Health Sci       Date:  2021-04-16

3.  Relaxin does not prevent development of hypoxia-induced pulmonary edema in rats.

Authors:  Ute Kowalleck; Mohamed A Abdalla Ahmed; Julia Koedel; Katrin Schierle; Aida Salameh; Beate Rassler
Journal:  Pflugers Arch       Date:  2022-07-02       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.